234 related articles for article (PubMed ID: 32401385)
1. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
2. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
5. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
7. Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease.
Dore MP; Pedroni A; Pes GM; Maragkoudakis E; Tadeu V; Pirina P; Realdi G; Delitala G; Malaty HM
Dig Dis Sci; 2007 Feb; 52(2):463-8. PubMed ID: 17211695
[TBL] [Abstract][Full Text] [Related]
8. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Gold BD; Pilmer B; KierkuĊ J; Hunt B; Perez MC; Gremse D
Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
[TBL] [Abstract][Full Text] [Related]
9. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD; Scott LJ
Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.
Kinoshita Y; Miwa H; Sanada K; Miyata K; Haruma K
J Gastroenterol; 2014 Apr; 49(4):628-37. PubMed ID: 23653056
[TBL] [Abstract][Full Text] [Related]
12. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
14. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
15. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Wittbrodt ET; Baum C; Peura DA
Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
[TBL] [Abstract][Full Text] [Related]
16. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
Takenaka R; Okada H; Kawano S; Komazawa Y; Yoshinaga F; Nagata S; Inoue M; Komatsu H; Onogawa S; Kushiyama Y; Mukai S; Todo H; Okanobu H; Manabe N; Tanaka S; Haruma K; Kinoshita Y
World J Gastroenterol; 2016 Jun; 22(23):5430-5. PubMed ID: 27340360
[TBL] [Abstract][Full Text] [Related]
18. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
Oldfield EC; Parekh PJ; Johnson DA
Expert Rev Gastroenterol Hepatol; 2016 Oct; 10(10):1083-1089. PubMed ID: 27580358
[TBL] [Abstract][Full Text] [Related]
19. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Fass R; Frazier R
Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
[TBL] [Abstract][Full Text] [Related]
20. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]